Kisqali (ribociclib)

Kisqali (Ribociclib) is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed for the treatment of hormone receptor (HR)-positive, HER2-negative breast cancer. It works by targeting CDK4 and CDK6 proteins, which are essential regulators of cell division. By inhibiting these proteins, Kisqali helps stop the uncontrolled growth and proliferation of cancer cells, providing a targeted approach to breast cancer treatment.

Kisqali is commonly prescribed in combination with endocrine therapies, such as aromatase inhibitors or fulvestrant, for patients with early-stage high-risk breast cancer and advanced or metastatic disease. This combination approach has demonstrated significant clinical benefits by enhancing disease control and delaying cancer progression.

Administered orally, Kisqali offers a convenient treatment option supported by extensive clinical evidence. Studies have shown that Kisqali can significantly improve progression-free survival and overall survival in eligible patients, making it one of the leading targeted therapies in hormone receptor-positive breast cancer management.

As a cornerstone therapy in precision oncology, Kisqali represents a major advancement in breast cancer treatment by combining targeted inhibition of cancer cell growth with proven clinical efficacy. Its established safety profile, oral administration, and ability to improve long-term outcomes continue to make it an important option for healthcare professionals and patients seeking effective, personalized cancer care.